Digitizing the Biopharmaceutical Supply Chain Improves Resilience

Digitizing the biopharmaceutical supply chain is pivotal for industry resilience, responding to global challenges and disruptions. Deloitte's research, based on a survey of 100 biopharmaceutical leaders, explores the significance of supply chain digitization. Laks Pernenkil, Principal at Deloitte, discusses how the industry evolved, especially post-COVID, facing supply chain constraints and inflationary pressures. The transformation from linear to networked supply chains, facilitated by digitalization, enhances visibility, harmonizes processes, and improves asset efficiency. Companies are investing in end-to-end digitization, with 20% achieving scalable deployment. The competitive advantage lies in understanding and leveraging digitization for resilience, exemplified by an emerging therapy company. Beyond minimizing errors, digitization yields benefits in risk management, collaboration, workforce efficiency, and future-proofing supply chains.